Cat. No. 2242
Alternative Names: (±)-p-Octopamine, Epirenor, Norfen
Chemical Name: α-(Aminomethyl)-4-hydroxybenzenemeth
Biological ActivityInvertebrate biogenic amine neurotransmitter, related to noradrenalin, that is an adrenoceptor agonist. Stimulates lipolysis in mammalian adipocytes via activation of β3 receptors. Has dual effect on glucose transport in adipocytes: inhibits transport via β3 receptor activation but stimulates transport when oxidized by MAO. Also activates human α2A receptors, inhibiting subsequent cAMP production.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Visentin et al (2001) Dual action of octopamine on glucose transport into adipocytes: inhibition via β3-adrenoceptor activation and stimulation via oxidation by amine oxidases. J.Pharmacol.Exp.Ther. 299 96. PMID: 11561068.
Carpene et al (1999) Selective activation of β3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Naunyn-Schmied.Arch.Pharmacol. 359 310.
Roeder (1999) Octopamine in invertebrates. Prog.Neurobiol. 59 533. PMID: 10515667.
Airriess et al (1997) Selective inhibition of adenylyl cyclase by octopamine via a human cloned α2A-adrenoceptor. Br.J.Pharmacol. 122 191. PMID: 9313925.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Octopamine hydrochloride from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Octopamine hydrochloride, supplier, Invertebrate, biogenic, amine, activates, β3-adrenoceptors, β3-adrenoceptor, b3-adrenoceptors, alpha2A-adrenoceptors, a2a-adrenoceptors, a2a-adrenergic, alpha2a-adrenergic, β3-adrenergic, b3-adrenergic, Receptors, TAAR1, Tocris Bioscience, Adrenergic β3 Receptor Agonist products
Find multiple products by catalog number
April 1 - 5, 2017
Washington, D.C., USA